Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 93

1.

Modified Folfox6 as Adjuvant Chemotherapy in Vietnamese Patients With Colorectal Cancer.

Nguyen TQ, Bui TO, Tran PT, Tran VT, Nguyen VH, Chu QH, Bui TAT, Le NQ, Le VQ, Dao VT.

Cancer Control. 2019 Jan-Dec;26(1):1073274819864111. doi: 10.1177/1073274819864111.

2.

Elevation of preoperative s-CEA concentration in stage IIA colorectal cancer can also be a high risk factor for stage II patients.

Kim CW, Yoon YS, Park IJ, Lim SB, Yu CS, Kim JC.

Ann Surg Oncol. 2013 Sep;20(9):2914-20. doi: 10.1245/s10434-013-2919-4. Epub 2013 Jun 13.

PMID:
23760586
3.

[Adjuvant chemotherapy comprising modified FOLFOX6 after curative resection of synchronous or metachronous metastasis from colorectal cancer].

Hatano S, Ishibashi K, Amano K, Ishiguro T, Kuwabara K, Sobajima J, Ohsawa T, Okada N, Kumagai Y, Kumamoto K, Baba H, Tsuji Y, Haga N, Ishida H.

Gan To Kagaku Ryoho. 2012 Nov;39(12):2192-4. Japanese.

PMID:
23268020
4.

Feasibility of mFOLFOX6 as the adjuvant treatment after curative resection of metastases from colorectal cancer in Japanese patients.

Machida N, Yoshizaki K, Boku N, Yamazaki K, Onozawa Y, Fukutomi A, Yasui H, Taku K.

Int J Clin Oncol. 2013 Apr;18(2):279-84. doi: 10.1007/s10147-012-0374-z. Epub 2012 Feb 25.

PMID:
22367535
5.

Safety of mFOLFOX6/XELOX as adjuvant chemotherapy after curative resection of stage III colon cancer: phase II clinical study (The FACOS study).

Kosugi C, Koda K, Ishibashi K, Yoshimatsu K, Tanaka S, Kato R, Kato H, Oya M, Narushima K, Mori M, Shuto K, Ishida H.

Int J Colorectal Dis. 2018 Jun;33(6):809-817. doi: 10.1007/s00384-018-2979-9. Epub 2018 Feb 27.

PMID:
29484450
6.

Postoperative adjuvant chemotherapy in rectal cancer operated for cure.

Petersen SH, Harling H, Kirkeby LT, Wille-Jørgensen P, Mocellin S.

Cochrane Database Syst Rev. 2012 Mar 14;(3):CD004078. doi: 10.1002/14651858.CD004078.pub2. Review.

7.

A randomised controlled trial to assess the cost-effectiveness of intensive versus no scheduled follow-up in patients who have undergone resection for colorectal cancer with curative intent.

Mant D, Gray A, Pugh S, Campbell H, George S, Fuller A, Shinkins B, Corkhill A, Mellor J, Dixon E, Little L, Perera-Salazar R, Primrose J.

Health Technol Assess. 2017 May;21(32):1-86. doi: 10.3310/hta21320.

8.

[Prognostic factors for long-term outcome of hepatic resection for colorectal liver metastases].

Aldrighetti L, Castoldi R, Di Palo S, Arru M, Stella M, Orsenigo E, Gavazzi F, Ferla G, Di Carlo V, Staudacher C.

Chir Ital. 2005 Sep-Oct;57(5):555-70. Italian.

PMID:
16241086
9.

Clinical impact of adjuvant chemotherapy on patients with stage III colorectal cancer: l-LV/5FU chemotherapy as a modified RPMI regimen is an independent prognostic factor for survival.

Hotta T, Takifuji K, Arii K, Yokoyama S, Matsuda K, Higashiguchi T, Tominaga T, Oku Y, Yamaue H.

Anticancer Res. 2006 Mar-Apr;26(2B):1425-32.

10.

Cost-minimization analysis of adjuvant chemotherapy regimens given to patients with colorectal cancer in Japan.

Takata K, Fujita KI, Kubota Y, Ishida H, Ichikawa W, Shimada K, Sekikawa T, Taki-Takemoto I, Kamei D, Iwai S, Sasaki Y.

J Pharm Health Care Sci. 2016 Nov 9;2:30. eCollection 2016.

11.

Preoperative Serum Carcinoembryonic Antigen Level as a Prognostic Factor for Recurrence and Survival After Curative Resection Followed by Adjuvant Chemotherapy in Stage III Colon Cancer.

Kim CG, Ahn JB, Jung M, Beom SH, Heo SJ, Kim JH, Kim YJ, Kim NK, Min BS, Koom WS, Kim H, Roh YH, Ma BG, Shin SJ.

Ann Surg Oncol. 2017 Jan;24(1):227-235. doi: 10.1245/s10434-016-5613-5. Epub 2016 Oct 3.

PMID:
27699609
12.

Elevated preoperative serum carcinoembrionic antigen level may be an effective indicator for needing adjuvant chemotherapy after potentially curative resection of stage II colon cancer.

Ogata Y, Murakami H, Sasatomi T, Ishibashi N, Mori S, Ushijima M, Akagi Y, Shirouzu K.

J Surg Oncol. 2009 Jan 1;99(1):65-70. doi: 10.1002/jso.21161.

PMID:
18942720
13.

First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials.

Wasan HS, Gibbs P, Sharma NK, Taieb J, Heinemann V, Ricke J, Peeters M, Findlay M, Weaver A, Mills J, Wilson C, Adams R, Francis A, Moschandreas J, Virdee PS, Dutton P, Love S, Gebski V, Gray A; FOXFIRE trial investigators; SIRFLOX trial investigators; FOXFIRE-Global trial investigators, van Hazel G, Sharma RA.

Lancet Oncol. 2017 Sep;18(9):1159-1171. doi: 10.1016/S1470-2045(17)30457-6. Epub 2017 Aug 3.

14.

A randomized two arm phase III study in patients post radical resection of liver metastases of colorectal cancer to investigate bevacizumab in combination with capecitabine plus oxaliplatin (CAPOX) vs CAPOX alone as adjuvant treatment.

Snoeren N, Voest EE, Bergman AM, Dalesio O, Verheul HM, Tollenaar RA, van der Sijp JR, Schouten SB, Rinkes IH, van Hillegersberg R.

BMC Cancer. 2010 Oct 11;10:545. doi: 10.1186/1471-2407-10-545.

15.

Multicenter phase II study of modified FOLFOX6 as neoadjuvant chemotherapy for patients with unresectable liver-only metastases from colorectal cancer in Japan: ROOF study.

Takahashi T, Shibata Y, Tojima Y, Tsuboi K, Sakamoto E, Kunieda K, Matsuoka H, Suzumura K, Sato M, Naganuma T, Sakamoto J, Morita S, Kondo K.

Int J Clin Oncol. 2013 Apr;18(2):335-42. doi: 10.1007/s10147-012-0382-z. Epub 2012 Mar 2.

PMID:
22383023
16.

Deleted in colorectal cancer protein expression as a possible predictor of response to adjuvant chemotherapy in colorectal cancer patients.

Gal R, Sadikov E, Sulkes J, Klein B, Koren R.

Dis Colon Rectum. 2004 Jul;47(7):1216-24. Epub 2004 May 19.

PMID:
15148649
17.

Perioperative Serum Carcinoembryonic Antigen Ratio Is a Prognostic Indicator in Patients With Stage II Colorectal Cancer.

Woo J, Kim J, Park I, Cho H, Gwak G, Yang KH, Bae BN, Kim KH.

Ann Coloproctol. 2018 Feb;34(1):4-10. doi: 10.3393/ac.2018.34.1.4. Epub 2018 Feb 28.

18.

Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial.

Yamada Y, Takahari D, Matsumoto H, Baba H, Nakamura M, Yoshida K, Yoshida M, Iwamoto S, Shimada K, Komatsu Y, Sasaki Y, Satoh T, Takahashi K, Mishima H, Muro K, Watanabe M, Sakata Y, Morita S, Shimada Y, Sugihara K.

Lancet Oncol. 2013 Dec;14(13):1278-86. doi: 10.1016/S1470-2045(13)70490-X. Epub 2013 Nov 11. Erratum in: Lancet Oncol. 2014 Jan;15(1):e4.

PMID:
24225157
19.

Transient elevation in serum carcinoembryonic antigen while on adjuvant chemotherapy for colon cancer: Is this of prognostic importance?

Lawrence N, Hinder V, Murray M, Macapagal J, Thompson P, Sharples K, Findlay M.

Asia Pac J Clin Oncol. 2017 Apr;13(2):e124-e131. doi: 10.1111/ajco.12402. Epub 2015 Aug 6.

PMID:
26245738
20.

Supplemental Content

Support Center